Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Xentuzumab |
Synonyms | |
Therapy Description |
Xentuzumab (BI 836845) is a monoclonal antibody that binds to IGF-1 and IGF-2 and prevents binding to the IGF receptor (IGF-1R), resulting in decreased IGF-1R signaling (PMID: 32161368, PMID: 32054790). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Xentuzumab | BI 836845 | IGF1/2 Antibody 2 | Xentuzumab (BI 836845) is a monoclonal antibody that binds to IGF-1 and IGF-2 and prevents binding to the IGF receptor (IGF-1R), resulting in decreased IGF-1R signaling (PMID: 32161368, PMID: 32054790). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05110495 | Phase I | Xentuzumab | Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN) | Active, not recruiting | GBR | 0 |
NCT02204072 | Phase I | Enzalutamide Xentuzumab | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | Completed | USA | NLD | GBR | ESP | 4 |